Invitrogen’s $5M Man
Invitrogen CEO and chairman, Greg Lucier, made more than $5.4 million in 2006, according to the company’s proxy statement.
His base salary was $904,615, with the balance of his income coming from stock options, incentive payouts, and other compensation. David Hoffmeister, senior vice president and CFO, was the next highest paid executive at the company, pulling in $2.6 million.
According to the proxy statement, Ronald Matricaria made $274, 351, making him the highest paid board director after Lucier. The figure includes an annual cash compensation of $75,000, stock options, and other compensation. Four other directors made $246,184. The remaining three directors took home an average of $236,488.
On March 1, the company adopted new annual compensation guidelines stating each board director will receive a fixed annual compensation of $250,000 with 30 percent payable in cash and 70 percent in restricted stock.
Also, the company said last week Per Peterson has joined its board. Peterson recently retired from Johnson & Johnson as chairman of research and development where he was responsible for the corporate office of science and technology, the R&D council, and J&J’s cell therapy research work. Prior to J&J, he held various positions at Scripps Research Institute, the Wallenberg Laboratory, and the University of Uppsala in Sweden.
The company also announced the appointment of Kelli Richard as vice president, finance and chief accounting officer. Richard has been with Invitrogen since 2005 and was with Gateway before that.
Oxford Genome Sciences said this week it has appointed Mike Gresser to its scientific advisory board. Gresser is currently a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles. Before that, he held positions at Amgen as vice president , research for inflammation and head of neuroscience research. Gresser received his PhD in biochemistry from Brandeis University.